BioCentury
ARTICLE | Company News

Priority Review for Eagle's heat stroke treatment

March 27, 2017 6:32 PM UTC

FDA accepted and granted Priority Review to an NDA for Ryanodex dantrolene from Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat exertional heat stroke. Its PDUFA date is July 23.

The lyophilized formulation of dantrolene, a sodium muscle relaxant, is approved to treat and prevent malignant hyperthermia. It targets ryanodine receptor 1 (RyR1)...

BCIQ Company Profiles

Eagle Pharmaceuticals Inc.

BCIQ Target Profiles

Ryanodine receptor 1 (RyR1)